Skip to main content

Table 5 Characteristics of patients for miRNA study

From: Exome, transcriptome and miRNA analysis don’t reveal any molecular markers of TKI efficacy in primary CML patients

Patient Gender Age, years Sokal score TKI first line, dosage Efficient TKI
3 Female 57 Low risk Imatinib, 400 mg Optimal response
5 Female 68 Intermediate risk Imatinib, 400 mg Non-optimal response
7 Male 34 Intermediate risk Imatinib, 400 mg Non-optimal response
12 Female 38 Low risk Imatinib, 400 mg Optimal response
13 Female 26 Low risk Imatinib, 400 mg Optimal response
14 Male 56 Low risk Imatinib, 400 mg Optimal response
15 Female 65 Low risk Imatinib, 400 mg Optimal response
16 Female 32 High risk Imatinib, 400 mg Optimal response
17 Male 44 Low risk Imatinib, 400 mg Non-optimal response
18 Female 89 Low risk Imatinib, 400 mg Non-optimal response
19 Female 63 Intermediate risk Imatinib, 400 mg Non-optimal response
20 Male 49 Intermediate risk Imatinib, 400 mg Non-optimal response